On January 1, 2022, the former "sky-high drug" Nocinasin sodium injection was officially implemented at medical insurance prices, and the price dropped from the original 700,000 to more than 30,000 injections, and the Department of Medical Genetics of the Second Hospital of Zhejiang University also completed the treatment of the first batch of spinal muscular atrophy patients in The country in 2022.
Mr. Li is an old patient who has been ill for decades, and his sports performance has not been good since he was a child, and as he grows older, he feels that going up and down the stairs is becoming more and more laborious, and the distance that can continue to walk is also shortening. 10 years ago, he was diagnosed with "spinal muscular atrophy." However, due to the lack of effective treatment, in the previous nearly ten years, Mr. Li could only watch the strength of his legs gradually deteriorate.
In 2019, the first special drug for the treatment of spinal muscular atrophy, Northinalsan sodium injection, was listed in China, and Mr. Li, who was trapped in the abyss of rare diseases, saw a glimmer of hope in the cracks, but the sky-high price of "700,000 a needle" made this hope out of reach. On December 3, 2021, the National Medical Security Bureau announced the results of the adjustment of the national medical insurance drug list in 2021, and 7 rare disease drugs were newly added to the list, of which Nocinasin sodium underwent 8 rounds of price negotiations, and finally negotiated at a price of less than 34,000 yuan / needle.
Upon learning of this news, Mr. Li immediately contacted Professor Wu Zhiying, chairman of the Zhejiang Provincial Cooperation Group of the China Rare Disease Alliance and head of the Medical Genetics Department/Rare Disease Diagnosis and Treatment Center of the Second Hospital of Zhejiang University, and came to the Department of Medical Genetics of the Second Hospital of Zhejiang University, and he could not wait to use the drug on the first day after Nosina entered the medical insurance.
Professor Wu Zhiying said that the second hospital of Zhejiang University was the first batch of injected noncinsine drugs in China, which means that the inclusion of high-value drugs for rare diseases in medical insurance has achieved a new breakthrough, and China's SMA Diagnosis and Treatment officially announced that it has entered the era of medical insurance. Rare disease drug research and development is difficult, high amplitude, long cycle, has been difficult to meet the clinical needs of patients, timely research and development of listing, the price is often extremely expensive, drug accessibility is facing severe challenges, this medical insurance catalog adjustment, indicating that the country pays great attention to the rare disease patients this group, the new list of rare disease drugs well fill the gap in the domestic related rare disease treatment drugs, for clinical drugs provide options, for more rare disease patients to delay the development of the disease, improve the quality of life has brought hope.
Orange Persimmon Interactive City Express reporter Yu Xixi
Correspondent Fang Xu Zhu Junjun